Gary J. G. Atkinson
Gründer bei Zylö Therapeutic, Inc.
Ursprung des Netzwerks ersten Grades von Gary J. G. Atkinson
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 11 | |
Zylö Therapeutic, Inc.
 Zylö Therapeutic, Inc. BiotechnologyHealth Technology Zylö Therapeutic, Inc. develops a drug-delivery system designed to deliver notoriously hard-to-deliver therapeutic agents. The frim offers patented platform technology that leverages hydrogel-derived nanoparticles to deliver in a sustained and controlled manner therapeutic agents through topical administration, enabling the healthcare industry to harness the therapeutic potential across a variety of applications. The company was founded by Scott R. Pancoast, Joel M. Friedman, Adam Friedman, Lance M. White and Gary J. G. Atkinsonin November 2017 in and is headquartered in Greenville, SC.
5
| Holding Company | Biotechnology | 5 |
Quorex Pharmaceuticals, Inc.
 Quorex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quorex Pharmaceuticals, Inc. was previously engaged in discovering and developing drugs to address the growing need for new therapies to treat bacterial infections. The company's was purchased by Pfizer Inc in 2005. Quorex was headquartered in Carlsbad, CA.
3
| Extinct | Pharmaceuticals: Major | 3 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Gary J. G. Atkinson
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
Agouron Pharmaceuticals LLC
 Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| Rochester Christian University | College/University | Doctorate Degree | |
Metabasis Therapeutics, Inc.
 Metabasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Metabasis Therapeutics, Inc. engages in discovery, development and commercialization of novel drugs for metabolic diseases using the proprietary technology and the knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases. Metabasis was incorporated in April 1997 and is headquartered in La Jolla, CA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| XENCOR, INC. | Biotechnology | Corporate Officer/Principal | |
| University of Notre Dame | College/University | Undergraduate Degree | |
| GALERA THERAPEUTICS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Sofinnova Investments, Inc.
 Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Investment Managers | Corporate Officer/Principal | |
| George Washington University | College/University | Corporate Officer/Principal | |
| The California State University | College/University | Undergraduate Degree | |
| California State University-Sacramento | College/University | Undergraduate Degree | |
| Monterey Institute of International Studies | College/University | Masters Business Admin | |
| State University of New York at Buffalo | College/University | Doctorate Degree | |
| University of California San Diego | College/University | Doctorate Degree Corporate Officer/Principal Undergraduate Degree | |
| The University of Texas at Dallas | College/University | Doctorate Degree | |
Ascenta Therapeutics, Inc.
 Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Investment Trusts/Mutual Funds | Corporate Officer/Principal | |
Aspire IRB LLC
 Aspire IRB LLC Miscellaneous Commercial ServicesCommercial Services Aspire IRB LLC operates as an independent review board that provides human subject protection oversight in clinical trials for life science companies. The private company is based in San Diego, CA and has subsidiaries in the United States. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
Galen Management LLC
 Galen Management LLC Investment ManagersFinance Galen Management LLC (Galen Management) Is a private equity firm founded in 1990 by John Wilkerson and William Grant. The firm is headquartered in Stamford, Connecticut. | Investment Managers | Private Equity Investor | |
MPEX Pharmaceuticals, Inc.
 MPEX Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services MPEX Pharmaceuticals, Inc. develops and manufactures therapies for antibiotic resistance with focus on gram-negative organisms. It offers Aeroquin (MP- 376), an aerosol formulation of levofloxacin for the treatment of pulmonary infections in patients with cystic fibrosis, as well as antibiotic programs to address antibiotic resistance in gram negative organisms. The company was founded in 2001 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Oligonucleotide Therapeutics Society, Inc.
 Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
BioBlocks, Inc.
 BioBlocks, Inc. BiotechnologyHealth Technology Part of Genesis Biotechnology Group LLC, BioBlocks, Inc. is a collaborative medicinal chemistry research organization based in San Diego, CA. The company focuses on drug discovery from initial hit through identification of development candidates. BioBlocks provides expertise and joins forces with its clients to discover compounds qualified for advancement to phase two clinical trials. Aided by a results-based lead optimization model, BioBlocks scientists have developed multiple preclinical candidates for its partners. The company's leap-to-lead platform provides an alternative source for high-quality tractable leads with multiple possible optimization pathways. The company was founded in 2002 by Peter Pallai, who has been the CEO since 2002. BioBlocks was acquired by Genesis Drug Discovery & Development LLC on October 07, 2021. | Biotechnology | Corporate Officer/Principal | |
| CIDARA THERAPEUTICS, INC. | Pharmaceuticals: Other | Chief Executive Officer | |
| 4D PHARMA PLC | Pharmaceuticals: Major | Director/Board Member | |
| PARATEK PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
| IMAGO BIOSCIENCES, INC. | Biotechnology | Corporate Officer/Principal | |
| University of California Irvine School of Medicine | College/University | Masters Business Admin | |
Viracta Subsidiary, Inc.
 Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Biotechnology | Corporate Officer/Principal | |
| INMUNE BIO, INC. | Biotechnology | Director/Board Member | |
Cend Therapeutics, Inc.
 Cend Therapeutics, Inc. BiotechnologyHealth Technology Cend Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapies for solid tumor cancers. Its offers CendR Platform, which provides a targeted tissue penetration capability to specifically enhance drug delivery to tumors. Its lead compound CEND-1 seeks out tumors and activates the CendR transport pathway. The company was founded by Erkki Ruoslahti in 2016 and is headquartered in San Diego, CA. | Biotechnology | Chief Executive Officer | |
| The Immune Response Corporation, Inc. | Corporate Officer/Principal | ||
| HIGHTIDE THERAPEUTICS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
CDx Medical Holdings, Inc.
 CDx Medical Holdings, Inc. Medical/Nursing ServicesHealth Services CDx Medical Holdings, Inc. engages in the provision of healthcare services. The company is headquartered in Suffern, NY. | Medical/Nursing Services | Director/Board Member | |
CoImmune, Inc.
 CoImmune, Inc. Pharmaceuticals: MajorHealth Technology CoImmune, Inc. engages in manufacture and development of cell-based therapeutics. It offers warehouse management, processing suites, logistics, research labs, and qualification and validation. The company was founded in February 2019 and is headquartered in Durham, NC. | Pharmaceuticals: Major | Chairman | |
| Baracchini Consulting LLC | Corporate Officer/Principal | ||
| LISATA THERAPEUTICS, INC. | Pharmaceuticals: Major | President | |
| Lisata Therapeutics Australia Pty Ltd. | Chairman | ||
| DS Lifescience Consulting | Corporate Officer/Principal | ||
| The Agouron Institute | Corporate Officer/Principal | ||
| Antibiotics Working Group | Founder |
Statistik
International
| Vereinigte Staaten | 48 |
| Vereinigtes Königreich | 2 |
| China | 2 |
| Australien | 2 |
Sektoral
| Health Technology | 26 |
| Consumer Services | 11 |
| Commercial Services | 5 |
| Finance | 3 |
| Miscellaneous | 2 |
Operativ
| Director/Board Member | 53 |
| Corporate Officer/Principal | 50 |
| Chief Tech/Sci/R&D Officer | 19 |
| Chairman | 17 |
| Independent Dir/Board Member | 16 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Dan Kisner | 29 |
| Thomas A. Bologna | 18 |
| Jeffrey Stein | 14 |
| Scott R. Pancoast | 13 |
| Edgardo Baracchini | 13 |
| Arthur Levin | 10 |
| David Slack | 10 |
| Daniel Ripley | 9 |
| Ethel M. Koczon | 9 |
| Krzysztof Appelt | 8 |
| Jon T. Holmlund | 6 |
| F. Andrew Dorr | 5 |
| Richard Geary | 5 |
| John A. McNeil | 3 |
| John Lind | 2 |
- Börse
- Insiders
- Gary J. G. Atkinson
- Unternehmensverbindungen